316 related articles for article (PubMed ID: 22197974)
1. Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG.
Semenova VA; Schiffer J; Steward-Clark E; Soroka S; Schmidt DS; Brawner MM; Lyde F; Thompson R; Brown N; Foster L; Fox S; Patel N; Freeman AE; Quinn CP
J Immunol Methods; 2012 Feb; 376(1-2):97-107. PubMed ID: 22197974
[TBL] [Abstract][Full Text] [Related]
2. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization.
Li H; Soroka SD; Taylor TH; Stamey KL; Stinson KW; Freeman AE; Abramson DR; Desai R; Cronin LX; Oxford JW; Caba J; Pleatman C; Pathak S; Schmidt DS; Semenova VA; Martin SK; Wilkins PP; Quinn CP
J Immunol Methods; 2008 Apr; 333(1-2):89-106. PubMed ID: 18304568
[TBL] [Abstract][Full Text] [Related]
3. Development & validation of a quantitative anti-protective antigen IgG enzyme linked immunosorbent assay for serodiagnosis of cutaneous anthrax.
Ghosh N; Gunti D; Lukka H; Reddy BR; Padmaja J; Goel AK
Indian J Med Res; 2015 Aug; 142(2):196-204. PubMed ID: 26354217
[TBL] [Abstract][Full Text] [Related]
4. Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.
Pittman PR; Fisher D; Quinn X; Schmader T; Barrera-Oro JG
Vaccine; 2013 Oct; 31(44):5009-14. PubMed ID: 24026013
[TBL] [Abstract][Full Text] [Related]
5. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen.
Quinn CP; Semenova VA; Elie CM; Romero-Steiner S; Greene C; Li H; Stamey K; Steward-Clark E; Schmidt DS; Mothershed E; Pruckler J; Schwartz S; Benson RF; Helsel LO; Holder PF; Johnson SE; Kellum M; Messmer T; Thacker WL; Besser L; Plikaytis BD; Taylor TH; Freeman AE; Wallace KJ; Dull P; Sejvar J; Bruce E; Moreno R; Schuchat A; Lingappa JR; Martin SK; Walls J; Bronsdon M; Carlone GM; Bajani-Ari M; Ashford DA; Stephens DS; Perkins BA
Emerg Infect Dis; 2002 Oct; 8(10):1103-10. PubMed ID: 12396924
[TBL] [Abstract][Full Text] [Related]
6. Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum.
Semenova VA; Steward-Clark E; Stamey KL; Taylor TH; Schmidt DS; Martin SK; Marano N; Quinn CP
Clin Diagn Lab Immunol; 2004 Sep; 11(5):919-23. PubMed ID: 15358653
[TBL] [Abstract][Full Text] [Related]
7. A two-stage, multilevel quality control system for serological assays in anthrax vaccine clinical trials.
Soroka SD; Schiffer JM; Semenova VA; Li H; Foster L; Quinn CP
Biologicals; 2010 Nov; 38(6):675-83. PubMed ID: 20875951
[TBL] [Abstract][Full Text] [Related]
8. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice.
Sloat BR; Cui Z
J Pharm Pharmacol; 2006 Apr; 58(4):439-47. PubMed ID: 16597361
[TBL] [Abstract][Full Text] [Related]
10. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
[TBL] [Abstract][Full Text] [Related]
11. Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine.
Gubbins MJ; Schmidt L; Tsang RS; Berry JD; Kabani A; Stewart DI
J Immunoassay Immunochem; 2007; 28(3):213-25. PubMed ID: 17613668
[TBL] [Abstract][Full Text] [Related]
12. The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine.
Lininger LA; Cullum ME; Lyles MB; Bienek DR
Vaccine; 2007 Feb; 25(9):1619-25. PubMed ID: 17150286
[TBL] [Abstract][Full Text] [Related]
13. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ
Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051
[TBL] [Abstract][Full Text] [Related]
14. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
Doolan DL; Freilich DA; Brice GT; Burgess TH; Berzins MP; Bull RL; Graber NL; Dabbs JL; Shatney LL; Blazes DL; Bebris LM; Malone MF; Eisold JF; Mateczun AJ; Martin GJ
J Infect Dis; 2007 Jan; 195(2):174-84. PubMed ID: 17191162
[TBL] [Abstract][Full Text] [Related]
15. Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice.
Pombo M; Berthold I; Gingrich E; Jaramillo M; Leef M; Sirota L; Hsu H; Arciniega J
Biologicals; 2004 Sep; 32(3):157-63. PubMed ID: 15536047
[TBL] [Abstract][Full Text] [Related]
16. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine.
Little SF; Ivins BE; Webster WM; Fellows PF; Pitt ML; Norris SL; Andrews GP
Vaccine; 2006 Mar; 24(14):2530-6. PubMed ID: 16417950
[TBL] [Abstract][Full Text] [Related]
17. Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax Infection.
Reed MD; Wilder JA; Mega WM; Hutt JA; Kuehl PJ; Valderas MW; Chew LL; Liang BC; Squires CH
PLoS One; 2015; 10(7):e0130952. PubMed ID: 26207820
[TBL] [Abstract][Full Text] [Related]
18. Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax.
Semenova VA; Schmidt DS; Taylor TH; Li H; Steward-Clark E; Soroka SD; Ballard MM; Quinn CP
Vaccine; 2007 Feb; 25(10):1780-8. PubMed ID: 17229495
[TBL] [Abstract][Full Text] [Related]
19. Validation of high throughput screening of human sera for detection of anti-PA IgG by Enzyme-Linked Immunosorbent Assay (ELISA) as an emergency response to an anthrax incident.
Semenova VA; Steward-Clark E; Maniatis P; Epperson M; Sabnis A; Schiffer J
Biologicals; 2017 Jan; 45():61-68. PubMed ID: 27814939
[TBL] [Abstract][Full Text] [Related]
20. Anthrax vaccine adsorbed: further evidence supporting continuing the vaccination series rather than restarting the series when doses are delayed.
Pittman PR; Cavicchia MA; Kingsbury JL; Johnson NA; Barrera-Oro JG; Schmader T; Korman L; Quinn X; Ranadive M
Vaccine; 2014 Sep; 32(39):5131-9. PubMed ID: 24837771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
